TargetMol

Thalidomide-O-amido-PEG4-C2-NH2

Product Code:
 
TAR-T39380
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T39380-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39380-500mg500mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized conjugate compound that combines a Thalidomide-based cereblon ligand with a linker commonly used in PROTAC technology. It acts as an E3 ligase ligand-linker conjugate, enabling targeted protein degradation.
CAS:
1957236-22-4
Molecular Weight:
550.565
Purity:
0.98
SMILES:
NCCOCCOCCOCCOCCNC(=O)COc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12

References

Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO2016105518A1. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.?Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11.